Although time to treatment discontinuation did not significantly differ between patients with latent tuberculosis on the basis of treatment regimen, interruptions in therapy varied by social and demographic factors.

Method for the detection of tuberculosis (TB) in children using modified FFP2 masks shows that children suffering from TB are unlikely to produce aerosols responsible for the transmission of this lung disease.

If there is one medical exam that everyone in the world has taken, it's a chest x-ray. Clinicians can use radiographs to tell if someone has tuberculosis, lung cancer, or other diseases, but they can't use them to tell if the lungs are functioning well.

For many years, the International Union Against Tuberculosis and Lung Disease (The Union) has pioneered capacity building in operational research. While there are many resources, a written, comprehensive guide has not been available.

• Tuberculosis (TB) makes 10 million people sick every year, and kills around 1.5 million people, more than any other infectious disease.  
• Drug resistant TB is a growing problem, with more than 400 thousand new cases annually, and more than 150 thousand deaths. 
• MTBVAC is a highly promising TB vaccine candidate that aims to prevent both drug sensitive and drug resistant TB in infants as well as in adolescents and adults.

O Porriño, 20th June 2024. Biofabri, a global human vaccine development company that is part of the Zendal group, and TBVI, a non-profit foundation facilitating the discovery and development of new TB vaccines that are globally accessible and affordable, have signed a contract with the European Health and Digital Executive Agency (HaDEA) under the EU4Health Programme to accelerate the final development of the MTBVAC vaccine. MTBVAC is a highly promising vaccine candidate that has the potential to be used as an alternative to BCG vaccination in infants and for prevention of TB disease in adolescents and adults. 

100 sponsored registrations will be offered to civil society members, individuals involved in efforts to address lung health, and survivors of TB. Deadline for applications: 18 July 2024

The TB Vaccine Advocacy Roadmap (TB Vax ARM) will host a webinar on 16 July 2024 on the latest updates in the TB vaccine space.

New Delhi: In a big victory for TB activism and children suffering from TB in India, the country’s patent office rejected Johnson & Johnson’s (J&J) patent application for the paediatric formulation of Bedaquiline on Friday, July 5.

South Africa's anti-trust regulator announced on July 5 that drugmaker Johnson & Johnson (J&J) and its subsidiary, Janssen Pharmaceutical, have agreed to withdraw a secondary patent on the tuberculosis (TB) drug bedaquiline.

The resurgence of detected TB infections after the pandemic has revealed persistent challenges in Southeast Asia, where socioeconomic factors exacerbate the disease's prevalence. Innovative strategies, such as AI-assisted detection and international cooperation, are critical to eliminating the scourge.